Health Trials

Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload

ConditionsAcute Decompensated Heart FailureVolume OverloadEdema
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCairo University

About this trial

This study aims to compare two medications, acetazolamide and metolazone, along with loop diuretics, to see which one works better and is safer for patients with ADHF who have volume overload. By comparing these medications, we hope to learn which one can help these patients the most. This will help doctors choose the best treatment for patients with ADHF and volume overload.

Eligibility criteria

Qualifiers

Male or female patients with ages ≥ 18 years old, and less than 65 years old.

For both elective and emergency hospital admissions, patients with a clinical diagnosis of ADHF must exhibit at least one clinical sign indicative of volume overload. These signs may include edema (score 2 or higher), ascites confirmed through echography, or pleural effusion confirmed by chest X-ray or echography or rales on auscultation, or jugular venous pressure greater than10 mm Hg.

Disqualifiers

Patient diagnosed with acute kidney injury upon hospital admission based on the presence of any of the following criteria: an increase in SCr by at least 0.3 mg/dL within 48 hours, an increase in SCr to at least 2 times the baseline value, known or presumed to have occurred within the prior 7 days, and a urine volume less than 0.5 ml/kg/hour for a duration of 6 hours.

Patients with acute pulmonary edema caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid accumulation.

Anticipated exposure to nephrotoxic agents (such as contrast dye) during hospitalization.

Patients who exhibit anuria or are undergoing renal replacement therapy or ultrafiltration.

Trial design

Treatments tested in this trial

  • Acetazolamide
  • Metolazone
  • IV Loop Diuretics

Treatment groups

110 Participants
are divided into 2 treatment groups

Locations

1
National Heart Institute3755204, GizaGZ, Egypt

Sponsors and collaborators

Cairo University

Lead sponsor

Misr International University

Sponsor institution

National Heart Institute, Egypt

Collaborator

Source ClinicalTrials.gov